Aquatic Capital Management LLC Purchases New Shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Aquatic Capital Management LLC acquired a new position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) during the fourth quarter, HoldingsChannel reports. The fund acquired 8,555 shares of the biopharmaceutical company’s stock, valued at approximately $101,000.

Several other large investors also recently made changes to their positions in the business. Altium Capital Management LLC raised its holdings in shares of Corbus Pharmaceuticals by 97.4% in the fourth quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company’s stock valued at $4,543,000 after buying an additional 190,000 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Corbus Pharmaceuticals by 5.5% in the fourth quarter. Geode Capital Management LLC now owns 263,532 shares of the biopharmaceutical company’s stock worth $3,110,000 after acquiring an additional 13,773 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Corbus Pharmaceuticals by 769.4% in the fourth quarter. Renaissance Technologies LLC now owns 139,100 shares of the biopharmaceutical company’s stock worth $1,641,000 after acquiring an additional 123,100 shares during the last quarter. HealthInvest Partners AB lifted its position in shares of Corbus Pharmaceuticals by 41.3% during the fourth quarter. HealthInvest Partners AB now owns 98,304 shares of the biopharmaceutical company’s stock worth $1,188,000 after purchasing an additional 28,731 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Corbus Pharmaceuticals by 4.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 97,882 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 4,239 shares during the last quarter. Institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Stock Performance

CRBP opened at $7.42 on Tuesday. The firm’s fifty day moving average is $6.39 and its two-hundred day moving average is $11.07. The firm has a market cap of $90.76 million, a PE ratio of -1.58 and a beta of 3.19. Corbus Pharmaceuticals Holdings, Inc. has a twelve month low of $4.64 and a twelve month high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.24. Equities analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Jefferies Financial Group dropped their price objective on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. StockNews.com raised Corbus Pharmaceuticals to a “sell” rating in a report on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and issued a $51.00 target price on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Finally, William Blair initiated coverage on shares of Corbus Pharmaceuticals in a research report on Friday, February 28th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $59.13.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.